Christopher M. Starr, Director at Monopar Therapeutics (MNPR), sold 16,800 shares at $40.00 ($672K) on 2025-07-14, disclosed to the SEC on 2025-07-16.
Seasonal sale ($672k) by Director — this insider has traded MNPR in July in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| RPTP | SELL | 2015-02-25 | $286K | — | Filing → |
| RPTP | SELL | 2015-02-19 | $281K | — | Filing → |
| RPTP | SELL | 2015-01-26 | $284K | — | Filing → |